History of the Project
The 2014 Florida Legislature appropriated $1 million in recurring General Revenue funds and $2 million in non-recurring funds to provide extended-release injectable naltrexone (VIVITROL®) to treat alcohol and opioid addicted offenders in community-based drug treatment programs. These funds were appropriated to the Office of the State Court Administrator (OSCA) who has contracted with the Florida Alcohol and Drug Abuse Association (FADAA) to establish a program enabling providers to access this medication. With dedicated resources made available by the Legislature to access this medication, there is an opportunity for providers to expand their clinical and medical protocols to use VIVITROL. FADAA has established a grant process for the selection of eligible providers and for the allocation and distribution of the funds.
From 2006 to 2008, FADAA, in collaboration and under contract with the Florida Department of Children and Families, participated in a national initiative, the Advancing Recovery Grant, funded by the Robert Wood Johnson Foundation to increase the effective use of evidence-based practices (EBP), specifically medication-assisted treatment with VIVITROL. FADAA’s role in this effort was three-fold:
1. Identify and engage a specific number of providers to participate in the pilot;
2. Organize and facilitate delivery of provider training on client selection, provider capacity requirements for participation, administration of the medication and developing a utilization and outcome tracking system; and
3. In conjunction with the Department, monitor the status of the project including identifying and remediating any local or state barriers to service delivery and to develop the infrastructure needed to implement the utilization of VIVITROL, such as identifying funding alternatives for the medication, including the use of the Indigent Drug Program.
The RWJ funded initiative resulted in positive client results, the creation of guidelines to approve provider agencies to access medications through the State Pharmacy, the development of procedures for medication purchase, and processes for identifying provider capacity to administer medication-assisted treatment. Subsequent to the end of the RWJ funded project, FADAA continued to work to sustain the use of VIVITROL with providers who participated in the RWJ pilot and to encourage the use of VIVITROL to additional providers. By 2009, the number of providers participating in the VIVITROL initiative increased by 50%.
For the past several years FADAA has been working with the Department of Corrections to establish a program to utilize VIVITROL for probationers in community drug treatment secure and non-secure residential treatment programs. FADAA worked with the Department of Corrections in developing a protocol to select providers that had the medical capacity to implement the program. With dedicated funding this past legislative session, FADAA is presently working with the Department to expand the number of providers utilizing the medication.
Office of State Courts Administrator (OSCA) Vivitrol® Program
The 2017 Florida Legislature appropriated $5 million recurring and $2.5 million non-recurring for this program. These funds were appropriated to the Office of the State Court Administrator (OSCA) who has contracted with the Florida Alcohol and Drug Abuse Association (FADAA) to establish a program enabling providers to access this medication. Providers are reimbursed for screening and assessing individuals for the appropriateness of administering Vivitrol®, for administration and cost of the medication, and for medical support and monitoring. These dedicated resources made available by the Legislature enable providers to expand their clinical and medical treatment protocols and make more treatment options available to the courts. From February 1, 2015 through the end of January 2018, a total of 4,664 individuals have been screened for services, 3,110 individuals have received medical assessments/labwork, and 2,250 patients have received 7,958 Vivitrol® injections.
The 2017 Florida Legislature appropriated $6.3 million in recurring general revenue for the Florida Department of Children and Families (DCF) to provide extended-release injectable Naltrexone (VIVITROL) to treat alcohol and opioid dependent individuals that are eligible for publicly funded behavioral health services. The DCF contracted with the Florida Alcohol and Drug Abuse Association (FADAA) to manage reimbursement of VIVITROL services to substance abuse treatment providers. The reimbursements cover the cost of client screenings, medical assessments, administration of the medication, and medical support and monitoring. From November 1, 2015 through the end of January 2018, a total of 2,053 individuals have been screened for services, 1,269 individuals have received medical assessments/labwork, and 1,056 patients have received 2,930 Vivitrol® injections.